Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

AI Briefing

• – Palvella Therapeutics secures European patent for anhydrous rapamycin compositions, bolstering global intellectual property protection for its lead product candidate QTORINTM, targeting serious, rare skin diseases and vascular malformations.
• – The patent issuance confirms Palvella's commitment to advancing its QTORINTM platform and its potential to address unmet medical needs in these areas.
• – The company's lead product candidate, QTORINTM rapamycin, is currently in development and has shown promise in preclinical studies for treating these rare conditions.